Effect of renal impairment on the pharmacokinetics of exenatide
about
The treatment of type 2 diabetes in the presence of renal impairment: what we should know about newer therapiesUpdate on the treatment of type 2 diabetes mellitusSystematic Literature Review of DPP-4 Inhibitors in Patients with Type 2 Diabetes Mellitus and Renal ImpairmentIn vitro metabolic stability of exendin-4: pharmacokinetics and identification of cleavage productsPharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus.Overview of Data Concerning the Safe Use of Antihyperglycemic Medications in Type 2 Diabetes Mellitus and Chronic Kidney Disease.Effect of renal impairment on the pharmacokinetics of the GLP-1 analogue liraglutide.Exenatide Use in the Management of Type 2 Diabetes Mellitus.Liraglutide - overview of the preclinical and clinical data and its role in the treatment of type 2 diabetes.Management of diabetes mellitus in patients with chronic kidney diseaseExendin-4 attenuates blast traumatic brain injury induced cognitive impairments, losses of synaptophysin and in vitro TBI-induced hippocampal cellular degenerationDiabetes treatment in patients with renal disease: Is the landscape clear enough?Selecting GLP-1 agonists in the management of type 2 diabetes: differential pharmacology and therapeutic benefits of liraglutide and exenatideEmerging treatment options for type 2 diabetesOral glucose-stimulated serum C-peptide predicts successful switching from insulin therapy to liraglutide monotherapy in Japanese patients with type 2 diabetes and renal impairmentEmerging role of GLP-1 receptor agonists in the treatment of obesity.Differentiating incretin therapies based on structure, activity, and metabolism: focus on liraglutide.Pharmacokinetic and pharmacodynamic modeling of exendin-4 in type 2 diabetic Goto-Kakizaki rats.Effect of hemodialysis on plasma glucose profile and plasma level of liraglutide in patients with type 2 diabetes mellitus and end-stage renal disease: a pilot studyChoosing between GLP-1 Receptor Agonists and DPP-4 Inhibitors: A Pharmacological Perspective.The efficacy of incretin therapy in patients with type 2 diabetes undergoing hemodialysis.Exenatide at therapeutic and supratherapeutic concentrations does not prolong the QTc interval in healthy subjects.Safety and efficacy of liraglutide in patients with type 2 diabetes and end-stage renal disease: protocol for an investigator-initiated prospective, randomised, placebo-controlled, double-blinded, parallel intervention study.Evolution of exenatide as a diabetes therapeutic.Effects of glucagon-like peptide-1 receptor agonists on renal functionA review of exenatide as adjunctive therapy in patients with type 2 diabetes.Population pharmacokinetics of exenatideEffects of once-weekly dulaglutide on kidney function in patients with type 2 diabetes in phase II and III clinical trials.Glucagon-like peptide-1 analog and insulin combination therapy in the management of adults with type 2 diabetes mellitus.Incretin-based therapies--review of the physiology, pharmacology and emerging clinical experience.The safety and tolerability of GLP-1 receptor agonists in the treatment of type 2 diabetes: a review.Emerging GLP-1 receptor agonists.Non-glycaemic effects mediated via GLP-1 receptor agonists and the potential for exploiting these for therapeutic benefit: focus on liraglutide.Incretin therapies in the management of patients with type 2 diabetes mellitus and renal impairment.GLP-1 agonists for type 2 diabetes: pharmacokinetic and toxicological considerations.Management of post-transplant diabetes.Achieving glycemic control in patients with type 2 diabetes and renal impairment.Discovery and development of exenatide: the first antidiabetic agent to leverage the multiple benefits of the incretin hormone, GLP-1.Noninsulin glucose-lowering agents for the treatment of patients on dialysis.Pharmacokinetic considerations for the treatment of diabetes in patients with chronic kidney disease.
P2860
Q26744317-91B73D4C-BFB7-40E7-8993-419DF34DB716Q28073342-8337A412-19E0-457C-B558-40012E39087AQ28075368-C7A058AD-6E27-4496-887F-B4D5102F18F9Q28543699-BCA9DEE8-4D05-4EA0-B2A4-0B0DB8E9D728Q30249371-DE1F6C5F-4644-4E07-9679-541C9514D55EQ31025919-2DECF8AC-D888-4A5E-8FFB-ABBF1711996EQ33608023-0CD9A5CA-9FCE-4886-B7A7-C642ABE31746Q33664114-E5D26997-AF58-44B6-9C9F-7AAB0C0ECE9FQ33785308-1A79EF92-E1FC-41B9-BD25-2AB95B1C8D9FQ33792375-5D3322DC-C513-4313-A40A-306142A68695Q33807853-6F59B3B4-1DDB-4319-85BC-BEBA6F00B7EFQ34068430-B967BEFC-98C9-420A-98A4-FA661E153352Q34133324-857E384A-AB19-4131-BB4E-4CC7F83F059BQ34381281-15E30EEB-4269-443A-AD9B-783449EA0090Q34407868-1CEACF1D-6D46-4933-B7FB-A378CE8845DBQ34620465-00D52E83-FCCA-4781-A30C-BB43FE276DDFQ34659509-759C844E-3220-487F-AD94-78D8EEAF7477Q34702329-BDD27409-436C-438B-91B1-E2BD166CF88BQ34744189-37919592-16A8-4084-A2EE-FF3C598620F1Q36355550-12708C6F-0971-48B3-8292-E8597B527780Q36686365-B003A2EA-DCCE-4169-8F0C-F116B4ABB424Q36729921-6A8ADC64-3F1A-4DF8-94A5-3F719CD07D06Q36809901-30D16D10-D650-406E-B7A8-ECF3ED2C43F1Q36877205-02755941-49F4-4610-94D5-9DD7D7E6E196Q37232679-F2A89A9C-71F7-4513-A4E2-A17F7D5B1B7AQ37403218-E4E22512-D92F-4A41-BFC2-2B601F34B5CFQ37639905-B02E4942-E2C8-4412-BC04-4A9A7D6B7B2EQ37696496-3E31FA92-4AA9-422D-A63A-F1EBE01A02ACQ37763417-3BFA3AEC-6043-4F71-B8D4-AF73502B8977Q37837059-E29EB172-5607-417F-93BC-7513D493D541Q37864256-28C1E554-B474-4250-9419-89242EAABB8AQ37929744-F83F3922-6FCA-42BB-9FF3-089971190139Q37992259-DCB6984D-2B48-4054-ADA4-D80FD6C70779Q38012068-5601BF4C-0BD7-4D99-8B5C-B3AE806DABF3Q38055195-BAFB986B-0660-4689-8896-16947418BF31Q38063169-5C7DDA66-0C88-44C1-A567-1F1F0D3DF130Q38065109-5305EDEE-CC47-49D6-8A89-405B3CBF04E3Q38066566-25478679-324C-45F5-8B51-BBBFBAF34717Q38077451-1D9CC0EF-0362-429C-9B15-2BA0FCDB30E0Q38086611-B1E77921-1CCD-438B-9612-F51B0322CBCC
P2860
Effect of renal impairment on the pharmacokinetics of exenatide
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh
2007年學術文章
@zh-hant
name
Effect of renal impairment on the pharmacokinetics of exenatide
@ast
Effect of renal impairment on the pharmacokinetics of exenatide
@en
type
label
Effect of renal impairment on the pharmacokinetics of exenatide
@ast
Effect of renal impairment on the pharmacokinetics of exenatide
@en
prefLabel
Effect of renal impairment on the pharmacokinetics of exenatide
@ast
Effect of renal impairment on the pharmacokinetics of exenatide
@en
P2093
P2860
P1476
Effect of renal impairment on the pharmacokinetics of exenatide
@en
P2093
Helle Linnebjerg
Kenneth Mace
Malcolm Mitchell
Prajakti A Kothare
Robert Lins
Shobha Reddy
Soomin Park
P2860
P304
P356
10.1111/J.1365-2125.2007.02890.X
P407
P577
2007-04-10T00:00:00Z